Skip to main content

Part of cannabis and small business and retail

Available now: Cannabis Professional, the authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Canopy Growth Corp. has signed a deal to buy Ebbu Inc., a Colorado-based hemp researcher, in a stock-and-cash deal worth more than $425-million.

Under the agreement, Canopy will pay $25-million in cash and issue 6,221,210 shares to Ebbu.

Story continues below advertisement

The company will also pay up to an additional $100-million if certain scientific-related milestones are achieved within two years of the deal closing.

Canopy will have the option of making the milestone payments in cash, shares or a combination of cash and shares.

Shares in Canopy closed at $64.90 on the Toronto Stock Exchange on Friday.

The company says the deal will help its hemp and THC-rich cannabis genetic breeding program, as well as other parts of its business.

“Beyond the technological edge this transaction provides, we are pursuing this acquisition because Canopy shares Ebbu’s core ethos of building consumer trust,” said Mark Zekulin, Canopy’s co-chief executive and president.

“We collectively believe consumer trust is achieved by driving the scientific agenda needed to build predictable, repeatable outcomes and layering on brand power.”

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter